Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma by Liz Hanson | May 27, 2022 | Uncategorized
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma by Liz Hanson | Apr 5, 2022 | Uncategorized
“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer by Liz Hanson | Mar 15, 2022 | Uncategorized
Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial https://pubmed.ncbi.nlm.nih.gov/35239416/
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma by Liz Hanson | Feb 1, 2022 | Uncategorized
Cholesterol Auxotrophy as a Targetable Vulnerability in Clear Cell Renal Cell Carcinoma by Liz Hanson | Dec 1, 2021 | Uncategorized
